{
  "retracted": false,
  "timestamp": 1555027200000,
  "updates": [
    {
      "timestamp": 1556345655470,
      "identifier": {
        "doi": "10.1007/s12325-019-00945-2"
      },
      "type": "correction"
    }
  ],
  "identifier": {
    "doi": "10.1007/s12325-019-00915-8"
  },
  "journal": "Advances in Therapy",
  "publisher": "Springer Science and Business Media LLC",
  "title": "Correction to: A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA"
}
